BMJ  2007;335:526 (15 September), doi:10.1136/bmj.39310.506308.AD

Editorials

Direct to consumer advertising of drugs in Europe

Evidence on its benefits and harms is available but is being ignored

The first 150 words of the full text of this article appear below.

The promotion of prescription drugs to the public ("direct to consumer advertising") is currently used only in the United States and New Zealand. A systematic review of the clinical and economic consequences confirmed that this form of advertising influences patient demand and doctors' prescribing behaviour, but evidence of health benefits or improvements in underuse was lacking.1 A more recent report from the Institute of Medicine confirmed that direct to consumer advertising increases the early use of new drugs and asked for a two year moratorium of such advertising for newly approved drugs.2 Requests were made to revise the legislation towards limiting or even banning such advertising both in the US and in New Zealand3 4 after rofecoxib (a heavily advertised drug) was withdrawn from the market because it increased heart attacks.5 A proposal to modify the current ban on direct to consumer advertising will be considered by the European parliament in . . . [Full text of this article]

Nicola Magrini, clinical pharmacologist1, Maria Font, pharmacist2

1 CeVEAS, NHS Centre for the Evaluation of the Effectiveness of Health Care, Modena Local Health Authority, 41100 Modena, Italy , 2 International Society of Drug Bulletins, Pharmaceutical Department, Verona Local Health Authority, 37122 Verona, Italy

n.magrini@ausl.mo.it


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Articles

Tooth and nail
Fiona Godlee
BMJ 2007 335: 0. [Extract] [Full Text]

The world of the market place
Jonathan V Howell
BMJ 2007 335: 683-684. [Extract] [Full Text] [PDF]

What have we learnt from Vioxx?
Harlan M Krumholz, Joseph S Ross, Amos H Presler, and David S Egilman
BMJ 2007 334: 120-123. [Extract] [Full Text] [PDF]

Grading quality of evidence and strength of recommendations
BMJ 2004 328: 1490. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Howell, J. V (2007). The world of the market place. BMJ 335: 683-684 [Full text]  

Rapid Responses:

Read all Rapid Responses

"Unbiased evidence based information"? I think not
Peter Martin
bmj.com, 14 Sep 2007 [Full text]
The information of the market place
Jonathan V. Howell
bmj.com, 14 Sep 2007 [Full text]
Partnerships for Drug Promotion
Eddie Vos
bmj.com, 19 Sep 2007 [Full text]
Re: "Unbiased evidence based information"? I think not
Tim Reed
bmj.com, 25 Sep 2007 [Full text]



Student BMJ

Intimate examinations

Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.

www.student.bmj.com

Listen to the latest BMJ Interview